Risk factors for second primary neoplasia of esophagus in newly diagnosed head and neck cancer patients: a case–control study by unknown
Chung et al. BMC Gastroenterology 2013, 13:154
http://www.biomedcentral.com/1471-230X/13/154RESEARCH ARTICLE Open AccessRisk factors for second primary neoplasia of
esophagus in newly diagnosed head and neck
cancer patients: a case–control study
Chen-Shuan Chung1, Li-Jen Liao2,3, Wu-Chia Lo2, Yueh-Hung Chou4, Yi-Chen Chang5, Yu-Chin Lin6, Wei-Fan Hsu1,
Pei-Wei Shueng7 and Tzong-Hsi Lee1*Abstract
Background: The prevalence of esophageal neoplasia in head and neck (H&N) cancer patients is not low; however,
routine esophageal surveillance is not included in staging of newly-diagnosed H&N cancers. We aimed to investigate the
risk factors for synchronous esophageal neoplasia and the impact of endoscopy on management of H&N cancer patients.
Methods: A total of 129 newly diagnosed H&N cancer patients who underwent endoscopy with white-light imaging,
narrow-band imaging (NBI) with magnifying endoscopy (ME), and chromoendoscopy with 1.5% Lugol’s solution, before
definite treatment were enrolled prospectively.
Results: 60 esophageal lesions were biopsied from 53 (41.1%) patients, including 11 low-grade, 14 high-grade
intraepithelial neoplasia and 12 invasive carcinoma in 30 (23.3%) patients. Alcohol consumption [odds ratio (OR)
5.90, 95% confidence interval (CI) 1.23-26.44], advanced stage (stage III and IV) of index H&N cancers (OR 2.98,
95% CI 1.11-7.99), and lower body mass index (BMI) (every 1-kg/m2 increment with OR 0.87, 95% CI 0.76-0.99)
were independent risk factors for synchronous esophageal neoplasia. NBI with ME was the ideal screening tool
(sensitivity, specificity, and accuracy of 97.3%, 94.1%, and 96.3%, respectively, for detection of dysplastic and
cancerous esophageal lesions). The treatment strategy was modified after endoscopy in 20 (15.5%) patients.
The number needed to screen was 6.45 (95% CI 4.60-10.90).
Conclusions: NBI-ME surveillance of esophagus should be done in newly-diagnosed H&N cancer patients,
especially those with alcohol drinking, lower BMI, and advanced stage of primary tumor.
Keywords: Image-enhanced endoscopy, Narrow-band imaging, Second primary tumor, Esophageal cancer, Head
and neck cancerBackground
Squamous cell carcinomas of the head and neck (H&N)
region and the esophagus are common dismal malignancies
globally, especially in the Western Pacific regions where
carcinogen uses such as drinking alcohol, cigarette smoking
and betel quid chewing are prevalent [1]. Mucosa of
the upper aerodigestive tract (UADT) may be exposed
to common carcinogens and at risk of early molecular
alterations without histopathological changes, followed by* Correspondence: thleekimo@yahoo.com.tw
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reproduction in any medium, provided the ormalignant transformation [2]. According to population-
based analyses, the risk and incidence of second primary
cancers of the index head and neck, or esophagus are
quite high [3-5], and without early detection, synchronous
or metachronous carcinogenesis may lead to poor prog-
nosis despite multidisciplinary treatment of the primary
cancers [6-8]. Even with traditional panendoscopy screening
for synchronous esophageal cancer, the treatment result
was still poor [6].
Recent advances in image-enhanced endoscopy (IEE)
have enabled precancerous or early cancerous lesions
visible more easily under endoscopic examination [9].
Using IEE examination, especially chromoendoscopy withLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Chung et al. BMC Gastroenterology 2013, 13:154 Page 2 of 9
http://www.biomedcentral.com/1471-230X/13/154Lugol’s solution and narrow-band imaging (NBI) system
with high-resolution magnifying endoscopy (ME), dys-
plastic or cancerous lesions, and tumor invasion could
be well delineated [9-17]. The prevalence of high
grade intraepithelial neoplasia or invasive carcinoma
of the esophagus in population at high risk, such as
alcoholics or H&N cancer patients, is around 3.2 to
28% by IEE screening [11]. To triage and allocate H&N
cancer patients at higher risk for esophageal neoplasia
to surveillance program becomes important and cost-
effective. However, routine application of endoscopic
surveillance of esophagus is not a consensus nowadays,
and which population benefit from the screening policy
has not been well defined.
Although previous studies have found certain risk
factors for synchronous esophageal neoplasia in H&N
cancer patients [12,13], there was no prospective study
using routine application of NBI-ME and Lugol’s chro-
moendoscopy screening with standardized pathological
classification. The aim of this prospective study was to
determine the prevalence and risk factors for synchron-
ous esophageal neoplasia and the impact of routine IEE
screening on the decision making for the management
of newly diagnosed H&N cancer patients.
Methods
Study population and data collection
We prospectively recruited 168 adults older than 20-year-
old who had newly diagnosed H&N cancers that were
confirmed by two otolaryngologists (L.-J. L., W.-C. L.)
from March 2010 to March 2012 at the Far Eastern
Memorial Hospital in New Taipei City, Taiwan. We
excluded patients with salivary gland tumors, who
needed emergent surgery for compromised airways or
tumor bleeding, allergic history to iodine and pregnant. A
total of 129 patients were referred to gastroenterologists
for IEE screening before treatment. The study population
was separated into two groups: H&N cancer patients
with, and without synchronous esophageal neoplasia.
Demographic characteristics, including age, gender, body
mass index (BMI), and the status of habitual use of com-
mon carcinogens for UADT cancers, including drinking
alcohol, cigarette smoking, and betel quid chewing, were
gathered. The cumulative lifetime exposure was calculated
by multiplying the frequency and duration, and further
categorized into these three levels (Table 1 footnotes). All
the participants provided written informed consent before
endoscopic examination. This study was approved by
the Research Ethics Review Committee of Far Eastern
Memorial Hospital (FEMH IRB-101022-E).
Endoscopic examinations by IEE
All of the patients received endoscopic examinations
with NBI and ME which has powerful 80 times opticalmagnification (EVIS LUCERA CLV-260NBI, GIF-H260Z
endoscopy, Olympus Medical Systems Corp, Tokyo,
Japan), and chromoendoscopy with Lugol’s solution
(Sigma-Aldrich, St. Louis, Missouri, USA). All endo-
scopic examinations were performed by one well-
trained endoscopist (C.-S. C.). First, the oral cavity,
oropharynx and hypopharynx were evaluated under
NBI system [14,15]. The nasopharynx was not exam-
ined by endoscopy, but by otolaryngologists. Secondly,
the esophagus was examined by white-light imaging
(WLI) endoscopy from the esophageal inlet to the eso-
phagogastric junction, and then repeatedly evaluated
backward under NBI-ME. After NBI examination, we
switched back to WLI and sprayed 10 to 20 mL of 1.5%
Lugol solution evenly over the mucosa from esophago-
gastric junction to upper esophagus. The criteria of
suspected lesions were defined as a hyperemic change,
uneven or nodularity of mucosa under WLI system
(Figure 1A), or brownish discoloration of mucosa with
abnormal epithelial capillary pattern (Inoue’s Classifica-
tion type III ~ V) under NBI-ME system (Figure 1B and
1C) [9,10,16,17], or a well-demarcated Lugol-unstained
area (Figure 1D) with a diameter greater than 5 mm or
any Lugol-voiding lesions accompanied with pink-silver
sign which is often associated with high-grade neopla-
sia [18]. Finally, the stomach, and the first and second
portion of the duodenum, were examined under WLI
using the typical panendoscopic procedure. Endoscopic
biopsy was done for all suspected lesions fulfilling the
criteria mentioned above with histological results
served as reference standard.Histopathology and decision making of the treatment
strategy
The biopsied tissues were examined by an experienced
pathologist (Y.-H.C.) and classified by the revised Vienna
classification of epithelial neoplasia [19]. Chronic inflam-
mation and squamous hyperplasia belong to the diagnosis
of indefinite for neoplasia. Esophageal invasive carcin-
oma and squamous dysplasia which are associated with
increased risk for developing malignancy were included
for risk analysis [20]. The 7th edition of the American
Joint Committee on Cancer (AJCC) and the International
Union for Cancer Control tumor-node-metastasis system
was used for tumor staging [21], and the treatment
planning for head and neck cancer patients was made
by tumor board review. After a complete review of
the medical condition of each patient and the in-
formation from local findings, endoscopic and radio-
logical examinations, the final treatment option for
H&N cancer patients were discussed and made by
gastroenterologists, radio-oncologists, surgical and medical
oncologists.
Table 1 Demographic characteristics and risk assessment of the study population
Presence of esophageal neoplasia*
(n=30) No. of patients (%)
Absence of esophageal neoplasia*
(n=99) No. of patients (%)
OR (95% CI) P-value
Age (years, mean±SD) 58.76 ± 9.20 55.63 ± 9.99 1.03 (0.99-1.08) 0.130
<45 1 (3.3) 12 (12.1) referent
45~54 10 (33.3) 40 (40.4) 3.00 (0.34-26.82)
≧55 19 (63.3) 47 (47.5) 4.85 (0.56-41.94) 0.077
Sex
Female 2 (6.7) 5 (5.1) referent
Male 28 (93.3) 94 (94.9) 0.74 (0.14-4.05) 0.733
BMI (kg/m2, mean±SD) 21.64 ± 3.37 24.30 ± 4.85 0.86 (0.77-0.96)+ 0.008
Location of H&N cancer
Oral cavity 8 (26.7) 55 (55.6) Referent
Oropharynx 6 (20) 16 (16.2) 1.50 (0.34-6.59) 0.591
Hypopharynx 12 (40) 20 (20.2) 4.52 (1.46-13.99) 0.009
Larynx 4 (13.3) 4 (4.0) 5.70 (1.08-29.99) 0.040
Nasopharynx 0 4 (4.0) NA NA
Stage of H&N cancer
I 4 (13.3) 19 (19.2)
Referent
II 4 (13.3) 14 (14.1)
III 4 (13.3) 12 (12.1)
2.30 (0.98-5.42) 0.056
IV 18 (60.0) 51 (51.5)
Alcohol drinking
Non-drinker 3 (10) 32 (32.3) Referent
Drinker 27 (90) 67 (67.7) 4.10 (1.16-14.56) 0.029
Light to moderate 2 (6.7) 10 (10.1) 2.13 (0.30-15.12)
Heavy 25 (83.3) 57 (57.6) 4.68 (1.26-17.44) 0.009
Betel quid chewing
Non-chewer 17 (56.7) 33 (33.3) Referent
Chewer 13 (43.3) 66 (66.7) 0.37 (0.16-0.84) 0.018
Light to moderate 4 (13.3) 31 (31.3) 0.25 (0.07-0.87)
Heavy 9 (30.0) 35 (35.4) 0.50 (0.19-1.30) 0.108
Cigarettes smoking
Non-smoker 3 (10) 18 (18.2) Referent
Smoker 27 (90) 81 (81.8) 1.87 (0.51-6.86) 0.348
Light to moderate 21 (70) 60 (60.6) 2.10 (0.55-7.97) 0.528
Heavy 6 (20) 21 (21.2) 1.71 (0.37-8.05)
Number of exposure
None 1 7 Referent
1 1 10 0.70 (0.03-14.35)
2 18 42 3.00 (0.33-27.09)
3 10 40 1.75 (0.19-16.29) 0.680
Abbreviation: BMI body mass index, H&N head and neck, NA not applicable, OR odds ratio, CI confidence interval.
*Including low-grade, high-grade intraepithelial neoplasia and invasive carcinoma; + Risk assessment every 1-kg/m2 increment.
Note that the lifestyle risk factors were recorded according to the frequencies (alcohol on a weekly basis where one time indicates at least 15.75 gm of ethanol: 0,
never; 1, once; 2, once to twice; 3, 3–4 times; and 4, ≥5 times; betel quid on a piece per day basis: 0, never; 1, <1 piece; 2, 1–10 pieces; 3, 11–20 pieces; and 4, >20
pieces; cigarettes on a pack per day basis: 0, never; 1, <0.5 pack; 2, 0.5–1 pack; 3, 1–2 packs; and 4, >2 packs) and duration (0, never; 1, <1 year; 2, 1–10 years; 3,
11–20 years; and 4, >20 years). The cumulative lifetime exposure was calculated by multiplying the frequency and duration, and further categorized into these
three levels: level 1, never (0); level 2, light to moderate (1–11); and level 3, heavy (≥12).
Chung et al. BMC Gastroenterology 2013, 13:154 Page 3 of 9
http://www.biomedcentral.com/1471-230X/13/154
Figure 1 Endoscopic surveillance and management of
synchronous high-grade intraepithelial neoplasia of esophagus
in a laryngeal cancer patient. A, A flat superficial neoplasia with
hyperemia in white-light imaging system. B, A superficial neoplasia
with brownish discoloration under narrow-band imaging system. C,
Lugol-voiding of the neoplasia after spraying a 1.5% Lugol’s solution.
D, Abnormal intraepithelial capillary loops under narrow-band
imaging system with magnifying endoscopy. E, Endoscopic
submucosal dissection of the superficial neoplasia. F, Mucosal cancer
invading the lamina propria (main picture: HE stain, 40x; right
bottom: HE stain, 100x).
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Continuous variables were expressed as mean ± standard
deviation and the comparisons between groups were
performed using the Student t-test; categorical variables
were summarized as count (%) and the comparisons
between groups were made using the χ2 or the Fisher’s
exact test when appropriate. Univariate and multivariate
logistic regression models were performed for evaluation
of the demographic and carcinogenic risk factors for
synchronous esophageal neoplasia in H&N cancer pa-
tients. Cochrane-Armitage trend test was used for the
investigation of the dose–response cancer risk predicting
power of carcinogens. The sensitivity, specificity and
accuracy of different IEE methods to detect esophageal
neoplasia were calculated according to the pathological
findings served as standard reference. A two-tailed p
value <0.05 was considered as statistically significant. The
statistical analysis was performed using STATA software
(version 11.0; Stata Corp, College Station, TX, USA).Results
The demographic characteristics of the study population
and risk assessment by univariate logistic regression
analysis of these factors are shown in Table 1. A total of
122 male and 7 female head and neck cancer patients were
enrolled. Sixty defined suspicious esophageal lesions were
biopsied from 53 (41.1%) patients after IEE screening
and 30 (23.3%) patients had the presence of dysplastic
or cancerous lesions by histopathological examination.
Compared with H&N cancer patients without synchron-
ous esophageal neoplasia, the mean age and sex ratio of
those with synchronous esophageal neoplasia were not
significantly different. However, the BMI is lower in the
group with synchronous esophageal neoplasia, and every
1-kg/m2 increment is associated with 0.86-fold lower
risk (p value = 0.008) for esophageal neoplasia (Table 1).
The frequency of patients with presence of synchronous
esophageal neoplasia was higher in those with hypophar-
yngeal cancer (12/32, 37.5%) and laryngeal cancer (4/8,
50%) than those with oral cavity cancer (8/63, 12.7%)
and oropharyngeal cancer (6/22, 27.3%) (Table 1). The
advanced stages, including 7th AJCC TNM stage III and
IV, were associated with increased risk (OR 2.30, 95% CI
0.98-5.42) for esophageal neoplasia, but not statistically
significant (p value = 0.056). Regarding the three common
carcinogen exposures, only drinking alcohol was associ-
ated with a higher risk (OR 4.10, 95% CI 1.16-14.56,
p value = 0.029) of esophageal neoplasia with a stepwise
dose–response relationship (p value for trend = 0.009).
Betel quid chewing was found to be associated with a
lower risk (OR 0.37, 95% CI 0.16-0.84, p value = 0.018)
of synchronous esophageal lesions. Compared with the
proportion of betel quid chewers in oral cavity cancer
subgroup, there were less betel quid chewers in the
hypopharyngeal (48.4% vs. 68.3%, p = 0.03) and laryngeal
cancer (25.0% vs. 68.3%, p = 0.01) subgroups (not shown
in Table 1). The number of concomitant carcinogens used
was not associated with an increased risk for esophageal
neoplasia.
In the multivariate logistic regression model (Table 2),
age, gender, cigarette smoking, betel quid chewing and
location of index H&N tumor were not associated with
the risk for synchronous esophageal neoplasia. However,
status regarding the drinking of alcohol (OR 5.90, 95%
CI 1.23-26.44, p = 0.020), lower BMI (every 1-kg/m2
increment with OR 0.87, 95% CI 0.76-0.99, p = 0.036),
and advanced stages (stage III&IV v.s. I&II) of index H&N
cancers (OR 2.98, 95% CI 1.11-7.99, p = 0.030) were asso-
ciated with higher risk for esophageal neoplasia.
The characteristics of the esophageal lesions detected
by IEE screening are summarized in Table 3. 15%, 43.3%
and 41.7% of the lesions were found at the upper, middle
and lower third of the esophagus, respectively. Among
them, 23.3% and 20.0% were high-grade intraepithelial
Table 2 Multivariate logistic regression model for risk
assessment*
Variables OR (95% CI) P-value
Age (≧55 vs. <55) 1.62 (0.59-4.44) 0.350
Gender (male vs. female) 0.17 (0.01-2.00) 0.161
BMI (1-kg/m2 increment) 0.87 (0.76-0.99) 0.036
Stage of H&N cancer (III&IV vs. I&II) 2.98 (1.11-7.99) 0.030
Alcohol drinking 5.90 (1.23-26.44) 0.020
Betel quid chewing 0.59 (0.21-1.65) 0.318
Cigarettes smoking 1.39 (0.29-6.60) 0.679
Hypopharyngeal cancer 1.52 (0.54-4.27) 0.423
Laryngeal cancer 4.41 (0.80-24.24) 0.088
Abbreviation: H&N head and neck, OR odds ratio, CI confidence interval.
*Risk assessment for esophageal low-grade, high-grade intraepithelial
neoplasia, and invasive carcinoma.
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respectively. Three esophageal lesions were Barrett’s
esophagus presented with intestinal metaplasia. To detect
low-grade intraepithelial neoplasia (LGIN), HGIN and
invasive carcinoma, the diagnostic performance of NBITable 3 Characteristics of esophageal lesions and
diagnostic performance of endoscopy
Esophageal lesions No. (%)
Histopathology
Total biopsied lesions 60 (100.0)
Chronic inflammation 3 (5.0)
Squamous hyperplasia 17 (28.3)
LGIN 11 (18.3)
HGIN 14 (23.3)
Invasive carcinoma 12 (20.0)
Others 3 (5.0)
Detection of neoplasia* No. (%) Sensitivity/ Specificity/
Accuracy (%)
Endoscopy/ Histopathology 60/37 (100) -
WLI 24/19 (51.4) 51.4 / 78.3 / 61.7
NBI-ME 37/36 (97.3) 97.3 / 94.1 / 96.3
LC 48/36 (97.3) 97.3 / 52.2 / 81.7
Location
Upper third 9 (15.0)
Middle third 26 (43.3)
Lower third 25 (41.7)




Abbreviation: WLI white-light imaging, NBI-ME narrow-band imaging system
with magnifying endoscopy, LC Lugol’s chromoendoscopy, LGIN low-grade
intraepithelial neoplasia, HGIN high-grade intraepithelial neoplasia.
*Detection of low-grade, high-grade intraepithelial neoplasia and invasive
carcinoma by histological confirmation.system with ME examination which had the sensitivity,
specificity, and accuracy of 97.3%, 94.1% and 96.3%,
respectively, was better than those of WLI system and
LC (Table 3). Seven patients (13.2%) had multifocal
esophageal lesions.
The treatment strategy had been modified in a total of
20 (15.5%) H&N cancer patients after the IEE examination.
The number needed to screen for synchronous esophageal
neoplasia to have a modified treatment strategy was 6.45
(1/15.5%, 95% CI = 4.60-10.90). The characteristics of
these patients are shown in Table 4. Among them, 4
patients had oral cavity cancer, 4 oropharyngeal cancer,
9 hypopharyngeal cancer, and 3 laryngeal cancer. For
the staging of the head and neck cancer, there were 4,
4, 4 and 8 patients with stage I, II, III and IV, respectively.
The esophageal lesions of these patients were four LGINs,
four HGINs, and twelve invasive carcinomas (3, 5, 1 and 3
patients with stage IA, IB, IIA, and IIIA, respectively).
Adding esophageal neoplasia into consideration for treat-
ment planning, five patients received extended radiation
field involving the esophageal lesions, six patients received
esophagectomy, and nine patients were suggested for
endoscopic treatment of the early esophageal neoplasia,
including radiofrequency ablation, endoscopic mucosal
resection or submucosal dissection (Figure 1E and 1F).
Discussion
The development of second primary malignancy of eso-
phagus, H&N region or lung in UADT cancer patients
is high [4,5,7,22,23]. A nationwide study in Taiwan, where
the prevalence of drinking alcohol, cigarette smoking
and betel quid chewing is high, has shown that the
standardized incidence ratio (SIR) of esophageal cancer
in patients with head and neck cancer is significantly
increased [4]. Supported by the concept of “field car-
cinogenesis” [2], cancer may develop synchronously or
metachronously in the UADT. Moreover, the survival
rate of those with second primary tumor, especially with
esophageal cancer, is significantly lower (5-year survival
rate only 6%) than those without second primary malig-
nancy [7,24]. Therefore, it is important to perform sur-
veillance of the esophagus in H&N cancer patients to
improve overall outcome. In this study, we have found
that drinking alcohol, lower BMI, and advanced stages
of the index H&N cancer were associated with a higher
risk for synchronous esophageal neoplasia, and the en-
doscopy examination by the NBI system with ME may
be the best screening modality available.
Carcinogen consumption largely contributes to the
development of the UADT malignancy, including the
cancer of H&N region and the esophagus [1]. Among
the common psychoactive substances, alcohol, tobacco
and betel nut are well-known carcinogens for the squamous
cell carcinoma of H&N region and the esophagus [1,11].
Table 4 Tumor board review of H&N cancer patients with modified treatment strategy after IEE screening
No. H&N cancer /
TNM stage
Location / size (cm) / pathology





1 Oropharynx / II Lower third / 0.3 / LGIN Tumor excision Tumor excision + EMR of esophageal lesion
2 Hypopharynx / I Middle third / 0.5 / LGIN Tumor excision Tumor excision + EMR of esophageal lesion
3 Oropharynx / III Lower third / 0.5 / LGIN Tumor excision + LN dissection
+ Adjuvant CCRT
Tumor excision + EMR of esophageal lesion +
Adjuvant CCRT
4 Hypopharynx / III Middle third / 6.0 / SCC (IIA) Tumor excision + LN dissection
+ Adjuvant CCRT
Tumor excision + Adjuvant CCRT with RT field
involving esophagus
5 Larynx / I Middle / 1.5 / HGIN Laryngectomy Laryngectomy + ESD of esophageal lesion
6 Larynx / I Upper / 6.0 / SCC (IB) Laryngectomy Laryngectomy + Esophagectomy + Adjuvant CCRT
7 Oropharynx / IVA Upper / 0.6 / SCC (IA) Neoadjuvant CCRT + Tumor
excision + LN dissection
Neoadjuvant CCRT + Tumor excision +
Esophagectomy
8 Oropharynx / II Middle / 4.0 / SCC (IA) Tumor excision + Adjuvant CCRT Tumor excision + Esophagectomy + Adjuvant CCRT
9 Hypopharynx/IVA Middle / 2.0 / HGIN Tumor excision + LN dissection
+ Adjuvant CCRT
Tumor excision + LN dissection + RFA of
esophageal lesion + Adjuvant CCRT
10 Hypopharynx / IVB Upper / 1.5 / SCC(IB) Definitive CCRT Definitive CCRT with RT field involving the
esophagus
11 Hypopharynx/III Middle / 5.0 / SCC (IIIA) Tumor excision + LN dissection
+ Adjuvant CCRT
Neoadjuvant CCRT + Tumor excision + LN
dissection + Esophagectomy
12 Hypopharynx / IVB Middle / 1.5 / SCC (IIIA) Definitive CCRT Definitive CCRT with RT filed involving the
esophagus
13 Oral cavity / II Lower / 0.2 / LGIN Tumor excision Tumor excision + EMR of esophageal lesion
14 Hypopharynx / III Middle / 0.8 / HGIN Tumor excision + LN dissection
+ Adjuvant CCRT
Tumor excision + LN dissection + ESD of
esophageal lesion + Adjuvant CCRT
15 Oral cavity / I Upper / 2.0 / SCC ( IB) Tumor excision Tumor excision + Esophagectomy
16 Oral cavity / II Middle / 1.0 / SCC (IA) Tumor excision Tumor excision + EMR of esophageal lesion
17 Oral cavity / IVB Middle / 2.0 / SCC (IIIA) Definitive CCRT Definitive CCRT with RT field involving esophagus
18 Hypopharynx / IVA Upper / 2.0 / SCC (IB) Tumor excision + LN dissection
+ Adjuvant CCRT
Tumor excision + LN dissection + Adjuvant CCRT
with RT field involving esophagus
19 Hypopharynx / IVA Middle / 0.8 / HGIN Tumor excision + LN dissection
+ Adjuvant CCRT
Tumor excision + LN dissection + EMR + Adjuvant
CCRT
20 Larynx / IVA Middle / 6.0 / SCC (IB) Laryngectomy + Adjuvant CCRT Laryngectomy + Esophagectomy + Adjuvant CCRT
Abbreviation: CCRT concurrent chemoradiotherapy, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, H&N head and neck, HGIN
high-grade intraepithelial neoplasia, IEE image-enhanced endoscopy, LN lymph node, LGIN low-grade intraepithelial neoplasia, RFA radiofrequency ablation, SCC
squamous cell carcinoma.
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was the independent risk factor for synchronous
esophageal neoplasia by univariate and multivariate
analyses (Table 1 and 2). Cigarette smoking and betel
quid chewing were not associated with higher risk for
synchronous second primary tumor of the esophagus in
multivariate logistic regression model. Besides, higher
cumulative doses of alcohol lead to a higher risk for
esophageal lesions (Table 1). Acetaldehyde, the inter-
mediate metabolite of the ethanol, is mainly responsible
for the systemic carcinogenic effect of alcohol [25,26].
The systemic effect of cigarette smoking and betel quit
chewing is not as conspicuous as ethanol; by contrast,
the inhaled tobacco smoke and topical contact of arecoline
in betel nut contributes to the cancer of the respiratory
tract, oral cavity and pharynx predominantly, rather than
the esophagus [7,25-27]. This hypothesis could explain thereason why drinking alcohol, but not cigarette smoking
or betel quid chewing, is associated with a higher risk
for esophageal neoplasia in H&N cancer patients. In our
study, betel quid chewing was found with lower risk for
synchronous esophageal neoplasia in the univariate
analysis (Table 1), but without statistical significance by
multivariate logistic regression model (Table 2). Because
in the univariate analysis, the hypopharyngeal and laryn-
geal cancers were associated with higher risk of esophageal
neoplasia than oral cavity cancer, the interesting finding
may result from lower proportion of betel quid chewers in
the hypopharyngeal and laryngeal cancer patients than
those in oral cavity cancer patients.
Regarding the location of H&N cancers, some researchers
have found the tendency of esophageal cancer in patients
with oropharyngeal and hypopharyngeal cancers, and the
tendency of lung cancer in patients with laryngeal cancer
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of the cancerization in respiratory and digestive axes [22],
other investigation did not report the similar result [4].
In a nationwide database study [4], the incidence of
second primary cancer is higher for esophageal cancer
(SIR 8.71, 95% CI 7.55-10.01) than for lung cancer (SIR
1.56, 95% CI1.34-1.80) in laryngeal cancer patients. In
our study, the fact that higher proportion of betel quid
chewing, which was negatively associated with risk of
second primary esophageal neoplasm (OR 0.37, 95% CI
0.16-0.84) for H&N cancer patients, in the oral cancer
group than the hypopharyngeal and laryngeal cancer
patients might be the reason why the esophageal
neoplasia less coexisted with oral cancer patients by
univariate analysis, and the locations of index H&N cancer
were not an independent risk factor for synchronous
esophageal neoplasia in multivariate analysis (Table 1
and 2). Moreover, cancers of hypopharynx and larynx
are more closely associated with alcohol consumption
than oral cancers [28], and alcohol was highly associated
with second primary neoplasia of esophagus in H&N
cancer patients by both univariate and multivariate
analyses in our result. The underlying pathogenesis
relationship between esophageal cancer and different
location of H&N cancer is still questionable.
Being overweight is a well-established risk factor for
several types of cancers, except for UADTcancer [29]. In a
collaborated cohort study conducted in the Asia-Pacific
region, the cancer risk and mortality rate were all higher
in those with excess bodyweight gain among 424,519 par-
ticipants, excluding lung and UADT cancer [29]. Another
multicenter case–control study conducted in European
countries has also revealed the inverse association of BMI
gain (BMI changes ≧5%) with UADT cancer risk (OR 0.74,
95% CI 0.62-0.89) [30]. Similar results have been reported
in a population-based case–control study [31]. BMI gain
of more than 25% was associated with a lower risk for lung
cancer (OR 0.53, 95% CI 0.33-0.84) and UADT cancers
(OR 0.44, 95% CI 0.27-0.71), especially in cigarette
smokers and alcohol drinkers [31]. In our study, we have
found that every 1-kg/m2 increment in BMI was inversely
associated with risk for synchronous esophageal neoplasia
(OR 0.87, 95% CI 0.76-0.99) in H&N cancer patients
(Table 2). Advanced stage of index H&N cancer was also
an independent risk factor for esophageal lesions. Because
UADT cancer related symptoms, such as odynophagia,
dysphagia or oral pain, may be accompanied with
decreased amount of oral intake, a lower BMI is usually
observed in UADT cancer patients. However, in our
study population, both lower BMI and advanced stage
of index H&N cancer were independent risk factors,
and most of the esophageal neoplasia detected were
early superficial lesions without obstruction signs. This
inverse association may indicate the body weight-relatedtumor biological pathway in cancerization of both H&N
and esophageal cancers.
IEE is a useful screening tool for precancerous or
cancerous gastrointestinal neoplasia. To detect esophageal
neoplasia in high risk population, Lugol’s chromoendo-
scopy which is one of the dye-based IEE techniques has
the sensitivity and specificity about 80.0-96.0% and
63.0-72.2%, respectively [11,32-34]. However, many side
effects, such as mucosal irritation, retrosternal chest
pain or burning sensation, laryngospasm or bronchospasm,
and even cardiac arrest, have been reported [18,35]. These
uncomfortable adverse effects and the low specificity
hinder the Lugol’s chromoendoscopy from being the
screening tool of esophageal neoplasia. On the contrary,
NBI system which is one of the equipment-based IEE
techniques has a higher sensitivity (88.9%) and specificity
(97.2%) for detecting esophageal neoplasia in high risk
populations [34]. By pushing a button on the handgrip of
the endoscope, esophageal neoplasia with hypervascularity
could be easily well-delineated without uncomfortable
side effects [9,17]. Moreover, the NBI system is not only
applied to the detection of early esophageal neoplasia
(accuracy 88.9%), but also superficial cancers of H&N
region (accuracy 86.7%) as well [14,15]. With the combin-
ation of magnifying endoscopy, the margin and invasiveness
of the neoplasia can be predicted accurately [9,16,33,34].
In our study, about 97.3 ~100% of esophageal neoplasia
were detected by NBI system with ME and Lugol’s chro-
moendoscopy. Only 51.4% of the esophageal neoplasia
were detected by the traditional WLI system. To screen
LGIN, HGIN and invasive carcinoma, NBI systems
with ME were shown to demonstrate a better diagnostic
performance than both WLI system and Lugol’s chro-
moendoscopy (Table 3). Thus, routine IEE surveillance
of the esophagus, especially using NBI system with ME
avoiding the unpleasant side effects from Lugol’s solution,
should be part of initial staging of H&N cancer patients.
Limitations
There were some limitations of this study. First, the
sample size of study population was small and it was
difficult to perform subgroup analysis for different location
of H&N cancer (Table 1). Larger scale investigation is
necessary to define H&N cancer patients with highest
risk for synchronous esophageal neoplasia. Secondly,
the result of this study disclosed the risk factors for
synchronous esophageal neoplasia and whether it is
true for metachronous lesions was not well-defined.
Third, the study was conducted in one single tertiary
hospital and all endoscopic examinations were done by
one well-trained endoscopist. Although all biopsied
suspicious esophageal lesions were defined by single
endoscopist, there would be no inter-observer bias in
this study. Finally, endoscopic surveillance of esophagus
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the treatment strategy at a high rate in the result. In
the result, four H&N cancer patients (two and one with
oropharyngeal cancers at stage II and III, respectively; one
with hypopharyngeal cancer at stage I) had synchronous
esophageal LGINs (Table 4). Because these esophageal
LGINs, which have a relative risk of 2.9 (95% CI 1.6-5.2)
for developing malignancy [20], were with small size
(≦0.5 cm) and presented in primary H&N cancers at
early stage, tumor board decision with curative endoscopic
ablation treatment were made. However, whether con-
comitant management of H&N cancers and synchronous
esophageal neoplasia has an impact on the survival still
needs longer follow-up study in the future.
Conclusions
The presence of synchronous esophageal neoplasia in H&N
cancer patients is not uncommon. Routine IEE surveillance
of the esophagus is very important to initial treatment
strategy of newly diagnosed H&N cancer patients, espe-
cially for those with alcohol drinking habit, lower BMI,
and advanced stage of index H&N tumor. We recommend
the routine surveillance of esophagus by performing NBI
system with ME examination in the initial staging workup
of newly diagnosed N&N cancer patients with risk factors
identified by this study, and the treatment of synchronous
neoplasia should be taken into consideration.
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